Replies to post #238897 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

hyperopia,

The combo trial has an NIH process patent attached to DCVax-L. That, I believe, is a safety enhancement that may be linked to other changes in the "art" from what the original Phase 3 patients received. I believe there is a risk for the comparison with the checkpoint inhibitors if an optimized L with optimized dosing schedule were to be compared to the combo. If "final negotiations" have taken this long then someone must be worried and I doubt it is the little guy. Best wishes.